SUNRISE patients who received Bavi+Doce, then anti-PDxx, have been surviving long, not even reaching median overall survival.
On April 4th, PPHM PRd: “...results of a new analysis of the Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)...Data demonstrated that for patients in the study's bavituximab plus docetaxel treatment arm who received subsequent immunotherapy, the median overall survival (mOS) was not reached”
We have already seen many studies that have shown us the benefits of I-O combinations that include anti-PS mAbs.
This should make the following PPHM ASCO 2017 data very interesting. What correlations? What biomarkers?
“Preliminary Correlative Analysis of PD-L1 Expression from the Sunrise Study”
Nikoletta Lea Kallinteris (1st Author), Peregrine Pharmaceuticals
IMO
sunstar
News 
Market Data 
Discover 
